Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Patients With Type 2 Diabetes Mellitus
Conditions
Interventions
LY3549492
Placebo
+2 more
Locations
1
Germany
Profil Institut für Stoffwechselforschung
Neuss, Germany
Start Date
May 9, 2022
Primary Completion Date
April 22, 2024
Completion Date
April 22, 2024
Last Updated
May 30, 2024
NCT06959901
NCT06574035
NCT06861062
NCT07336329
NCT04583800
NCT06251323
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions